Bococizumab is a promising novel monoclonal antibody designed to target and inhibit the activity of PCSK9. This targeted approach seeks to lower levels of lipid levels in patients with hypercholesterolemia, a condition characterized by elevated blood lipids. By blocking the action of PCSK9, bococizumab suppresses the degradation of LDL receptors… Read More